$IMUX News

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic Announces Presentation Of One Late-Breaking And Two Additional Posters Highlighting Additional Data From Its Phase 2 CALLIPER Trial

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO

B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27

Immunic Appoints Michael W. Bonney As Board Chairman

Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?

Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate

Immunic: Saved By A 200 Million Private Placement

Immunic CEO on Q1 highlights, new appointments and upcoming milestones

Immunic to Participate in Investor and Medical Conferences in May

HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer

Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy